Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CSL112

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

High Density Lipoproteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
Objective— CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2018
2018
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
Abstract CSL112 (Apolipoprotein A‐I [human]) is an intravenous preparation of apolipoprotein A‐I (apoA‐I), formulated with… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
2016
2016
Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112
RATIONALE CSL112, human apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine, is known to cause a dramatic rise in… Expand
Is this relevant?
2016
2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a…
BACKGROUND Despite aggressive pharmacotherapy and stenting, there is a residual risk of major adverse cardiovascular events among… Expand
Is this relevant?
2016
2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction
BACKGROUND Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2015
2015
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
BACKGROUND CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2015
2015
It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
  • Gunther Marsche
  • Journal of the American Heart Association
  • 2015
    • Corpus ID: 2477701
Clinical intervention studies have provided clear evidence that low‐density lipoproteins are causally involved in the development… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
OBJECTIVE The ability of apolipoprotein A-I (apoA-I) to transport cholesterol from atherosclerotic plaque is thought to underlie… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2014
2014
A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.
CSL112 is apoA-I purified from human plasma and reconstituted with phosphatidylcholine (PC) to form high-density lipoprotein (HDL… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
OBJECTIVE The ability of high-density lipoprotein (HDL) to remove cholesterol from atherosclerotic plaque is thought to underlie… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE